Autres troubles
Chapitre H.1
Edition en français
Traduction : Priscille Gérardin et Malaïka Lasfar Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA
Psychiatrie de l'enfant
Chapitre B.2
Edition en français
Traduction : Claire Rousseau
Sous la direction de : Priscille Gérardin
Avec le soutien de la SFPEADA
This guidance document is based on research of social media activity related to antibiotic use at EU level, as well as on a survey of the social media activities of EAAD partner organisations, mostly EU umbrella organisations of patients and health professionals. The research showed that there is al...ready some social media activity on prudent antibiotic use and that a few potential influencers are emerging. Similarly, the survey of the EU-wide partners of EAAD showed that respondents are becoming active on social media platforms.
more
Troubles du Développement
Chapitre C.2
Effective risk communication requires the alignment of complex factors including trust between the communicator and the audience(s), audience involvement, and emotional responses to risk. Risk communication is especially challenging now as new media changes the landscape for both
communicators and... their audiences. Viewed as a discussion of the most important findings for risk communicators and managers, this report delves into research-driven recommendations for effective risk communication practices.
more
Miscellaneous
Chapter J.2
This publication is intended for professionals training or practicing in mental health and not for the general public. The opinions expressed are those of the authors and do not necessarily represent the views of the Editor or IACAPAP. This publication seeks to describe the best treatments and pract...ices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and
laws of their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all dosages and unwanted effects are mentioned. Organizations, publications and websites are cited or linked to illustrate issues or as a source of further information. This does not mean that authors, the Editor or IACAPAP endorse their content or
recommendations, which should be critically assessed by the reader. Websites may also change or cease to exist.
more
Q3: Are pharmacotherapies safe and effective for the treatment of psychostimulant dependence (maintenance or relapse prevention) in non-specialized settings?
Chapter 2 in "Latest Findings in Intellectual and Developmental Disabilities Research" Edited by Üner Tan, ISBN 978-953-307-865-6, 404 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license | Intellectual and Developmental Disabilities presents reports on a wide rang...e of areas in the field of neurological and intellectual disability, including habitual human quadrupedal locomotion with associated cognitive disabilities, Fragile X syndrome, autism spectrum disorders, Down syndrome, and intellectual developmental disability among children in an African setting. Studies are presented from researchers around the world, looking at aspects as wide-ranging as the genetics behind the conditions to new and innovative therapeutic approaches. (All chapters available online: https://www.intechopen.com/books/latest-findings-in-intellectual-and-developmental-disabilities-research)
more
Q1: Are brief psychosocial interventions for people using cannabis or psychostimulants effective in reducing drug use, dependence and harm from drug use?
Participant Manual September 2012
Surveillance of Populations at High Risk for HIV Transmission
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international a...nd national levels.
Dementia is a syndrome that affects memory, thinking, behaviour and ability to perform everyday activities. The number of people living with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by 2050. Dementia is overwhelming not only for the people who have it, but also for their caregivers and families. There is lack of awareness and understanding of dementia in most countries, resulting in stigmatization, barriers to diagnosis and care, and impacting caregivers, families and societies physically, psychologically and economically.
Available Languages: Chinese, English, Japanese, Russian and Spanish
more
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo...r prophylaxis to prevent recurrence of simple or complex febrile seizures, which of the pharmacological interventions when compared with placebo/comparator produce benefit/harm in specified outcomes?
- continuous anticonvulsant therapy - intermittent anticonvulsant therapy - intermittent antipyretic treatment
more
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q9: For carers of people with dementia, do interventions (psychoeducational, cognitive-behavioural therapy counseling/case management, general support, training of caregivers, multi-component interventions and miscellaneous interventions) when compared to placebo/comparator, produce benefits/harm in... the specified outcomes?
more
Q8: For people with dementia, what is the role of a medical review (including comorbid physical and mental conditions and medication use)?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?